Patients who undergo cord-blood transplantation (CBT) offer a unique opportunity to improve our understanding of the impact of viral infection in the early stages of lymphocyte differentiation and function. Viral diseases, including EBV lymphoproliferative disorders, are a major cause of mortality after CBT. Different antiviral actors are involved in the surveillance of EBV infections. 1 While adoptive cellular immune response to EBV infection has been extensively studied, little is known about the role of innate immunity. Some evidence strongly suggests natural killer cell involvement, 2 whereas a role for gamma-delta (gd) T-cells in EBV surveillance has been poorly explored. Gamma-delta T cells are T lymphocytes that exhibit both innate and adaptive features. 3 They differ from conventional ab T cells not only in TCR composition, but also in their development, tissue distribution and physiological functions. The delta chain TCR structure defines two types of the gd sub-population: a sub-population that expresses the Vd2 chain mainly present in peripheral blood and another expressing Vd1, Vd3 or Vd5 chains (gd Vd2 neg ). The proliferation of gd Vd2 neg T cells has been described in various infections, including HIV 3 and CMV. 4 De Paoli et al. 5 have described an expansion of gd T cells during the acute phase of EBV-induced infectious mononucleosis, suggesting their possible role in the control of EBV infection. Interestingly, after birth, gd T cells exhibit an earlier activation and differentiation into the memory effector subtype than ab T cells. 6 Moreover, human gd Vd2 neg T cells exhibit cytotoxic activity in vitro against CMV and EBV lymphocyte cell lines (LCL). 4, 7 Consequently, we have hypothesized that these gd T cells could have also an important role in the surveillance of EBV infection after CBT.
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Gated on pan-γδ T cells We report here a 14-year-old girl, CMV neg , EBV pos , recipient of a 5/6 HLA-matched CBT for an acute T cell leukemia in relapse at 6 years from initial diagnosis. She underwent a myeloablative conditioning regimen including i.v. rabbit anti-thymocyte globulin (2.5 mg/kg/day, 3 days, Imtix-Sangstat, Lyon, France). She exhibited 100% full-donor chimerism since day 45 (D45) post CBT. She experimented extensive chronic GVHD since D120 post CBT treated with prolonged CsA and corticosteroids (Figure 1a) . This CMV neg patient presented EBV infection, which started at D31. She did not achieve EBV viral clearance until 2 years post transplant. EBV DNA viremia load peaks reached 4.8 Â 10 5 copies/mL at D93 (Figure 1a) . Surprinsingly, despite high EBV DNA load, she did not present clinical manifestation of EBV disease nor organ involvement except a multinodular spleen. At the onset of EBV infection, she exhibited profound T-lymphocyte deficiency (Figure 1a) . Within the 2 years of EBV infection, patient exhibited profound CD4 T-cell deficiency and did not develop EBV-specific T cells, as assessed both by Tetramer and ELISPOT-interferon-gamma assay, suggesting that innate immunity, mainly gd T cells, and natural killer cells, may have partially controlled EBV infection. Indeed, the proportion of gd T cells among CD3+ T cells increased progressively from 4 to 47% at 1 year (which corresponds to an ALC of 202/mm 3 ). The Vd2 neg subset represented more than 80% of the total circulating gd T cells at M3, M6 and M12 (Figure 1b) . This Vd2 neg subset appeared to be mostly differentiated into a CM subset, and activated as determined by the high expression of CD57 (35%, 21% and 31%, at respectively M3, M6 and M12), high expression of CD8 (up to 70% at M6), thought gd T cells can express CD8 after activation, 8 and low level of BTLA (6% at M6), a gd inhibitory receptor (J Gertner-Dardenne et al., manuscript in preparation). We therefore investigated whether these gd T cells were functional with respect to cytolytic function. Measurement of the gd T-cell degranulation activity (assessed by CD107a/b expression) point out a cytolytic activity against EBV þ cell line (verd EBV) compared with control cell line (P815) (Figure 1c) . Moreover, the expanded Vd2 neg subset appeared to be a Vd1 pos subset ( Figure 1c) . Thus, this CMV neg patient with EBV infection-but no other viral infection-underwent considerable late expansion of gd T cells from 4% at M3, up to 47% of total T cells at 1 year (vs median 2.6%±2.6) for other CB recipients (n ¼ 7)). Such expansion of gd T cells (up to 40% of total circulating T lymphocytes) has been previously described during CMV infection in transplanted recipient. 4 In our patient, most of the gd T cells were Vd1 pos , differentiated and highly activated (CD57 þ , CD8 þ , BTLA low ). Moreover, they were cytotoxic against EBV cell lines. Although the role of Vd2 neg gd T cells in the surveillance of CMV infection has been clearly demonstrated, 9 little is known about their role in the surveillance of EBV infection. Hacker et al. 10 have described that EBV-transformed LCLs could stimulate the Vd1 pos subset to proliferate in vitro. Recently, Fujishima et al. 7 have demonstrated in a patient who exhibited EBV disease after a BMT, the presence, at 10 years post BMT, of an oligoclonal population of Vd1 pos cells that exhibited in vitro cytotoxicity against autologous and allogenic EBV LCL in a 51 Cr-release assay. We demonstrate that Vd1 pos cells from CB expand early after CBT in setting of EBV infection and that, within the first year post CBT, gd T cells appeared to be differentiated, activated and functional. Collectively, these findings suggest that EBV-infected B cells may cause expansion and activation of Vd1 pos T cells in humans, although natural ligands for Vd1 pos TCR remain to be elucidated. Conversely Vd1 pos T cells may have a TCR repertoire against EBVinfected cells, and may play a role in post-transplant protection against EBV. This implies that enhancement of gd T-cell replication could be part of the mechanism that enhances the immune response to EBV.
